ADHD and Parkinson's treatments drive growth in CNS disorders market, report finds
Treatments for AD, ADHD and Parkinson\'s have been driving growth in the global central nervous system (CNS) disorders market, according to a report by Research and Markets of Dublin, Ireland.
Treatments for AD, ADHD and Parkinson's have been driving growth in the global central nervous system (CNS) disorders market, according to a report by Research and Markets of Dublin, Ireland.
According to the report, CNS Market Outlook to 2013, the global CNS market expanded by 8% in 2006, reaching total sales of $77.3bn in 2007.
The report finds that reimbursement terms continue to be favourable within the area, despite the relatively high risks associated with product development. High levels of investment have contributed to a rich product pipeline, with an estimated 600 clinical candidates currently under development. However, the sector has struggled as previously dominant products come under increasing pressure from generic competition and concerns about safety.
In spite of this, the CNS disorders market continues to be dominated by sales of original brands, which accounted for $53.5bn or 66.9% of the CNS market in 2007. Licensed and other brands recorded market shares of 10.7% and 9.2% respectively.
The US market accounted for the bulk of global sales in 2007, taking 59% or sales of $46.4bn. Germany led the major EU markets with a 5% share or sales of $3.7bn. Italy made the smallest contribution of the seven major markets having achieved sales of $1.4bn in 2007.
Schizophrenia treatments held the largest share of the CNS market with 27%, or sales of $20.7bn in 2007.
Treatments for Alzheimer's expanded by 21.3% between 2006 and 2007, recording total sales of $5.6bn. Steady growth is expected to continue from 2007 to 2013 due to growing patient numbers and the increasing level of r&d investment in this area.
Depression and insomnia were the only two CNS segments to experience falling sales in this period, declining by 4.5% and 8.5% respectively. Blockbuster patent expiries and the rise of generic competition had a significant impact upon both markets, the report says.
The ten leading companies represented 67.6% of the CNS disorders market in 2007. Johnson & Johnson currently leads the market with an 8% share driven by Risperdal.
The report profiles the factors and underlying trends shaping the market landscape and identifies the most promising areas of potential growth. Current leading brands of treatment within each indication are assessed and ten of the market's leading players are profiled. Sales forecasts for currently marketed and key pipeline products over the 2008-13 period are also provided.